TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
5.30
+0.12 (2.32%)
May 20, 2025, 4:00 PM - Market closed
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for TriSalus Life Sciences stock ranges from a low of $10 to a high of $12.5. The average analyst price target of $10.9 forecasts a 105.66% increase in the stock price over the next year.
Price Target: $10.90 (+105.66%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for TriSalus Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +107.55% | Mar 28, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +107.55% | Jan 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $10 | Buy | Initiates | $10 | +88.68% | Dec 17, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +107.55% | Nov 15, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +107.55% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
45.66M
from 29.43M
Increased by 55.13%
Revenue Next Year
68.81M
from 45.66M
Increased by 50.71%
EPS This Year
-0.63
from -1.31
EPS Next Year
-0.36
from -0.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|---|
| High | 50.7M | 88.8M | 111.9M | |||||
| Avg | 45.7M | 68.8M | 96.0M | |||||
| Low | 42.1M | 59.0M | 73.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|---|
| High | 72.3% | 94.5% | 62.7% | |||||
| Avg | 55.1% | 50.7% | 39.5% | |||||
| Low | 43.2% | 29.3% | 7.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.32 | -0.08 | 0.09 |
| Avg | -0.63 | -0.36 | 0.01 |
| Low | -0.88 | -0.59 | -0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.